Precision mRNA vaccine strategy shows early promise for improving TNBC relapse risk

	Oncology
	The latest oncology news from News Medical

	Precision mRNA vaccine strategy shows early promise for improving TNBC relapse risk An individualized neoantigen mRNA vaccine was tested in patients with early-stage triple-negative breast cancer and showed feasibility, safety, and strong T cell immune responses. Long-term follow-up suggested durable immune memory with encouraging relapse-free outcomes, though controlled trials are needed to confirm clinical benefit.

	Colonoscopy and FIT at age 60 catch colorectal cancer earlier The SCREESCO trial reveals that colorectal cancer screening at 60 enhances early diagnosis without affecting overall mortality or increasing long-term risks.

			Disordered lipid nanoparticles enhance RNA delivery efficiency The tiny fatty capsules that delivered COVID-19 mRNA vaccines into billions of arms may work better when they're a little disorganized.

			Genetic ancestry shapes acral melanoma biology and outcomes Genetic ancestry may play a key role in how acral melanoma, a rare and aggressive type of skin cancer, develops and behaves, with important implications for diagnosis and treatment, according to researchers at the Wellcome Sanger Institute, National Autonomous University of Mexico (UNAM) and their collaborators.

			Onset of "the munchies" after cannabis use could offer clues to help people with appetite loss The urgent onset of "the munchies" after cannabis use isn't imaginary – it's a cognitive response that occurs regardless of sex, age, weight or recent food consumption and could offer clues to help people struggling with appetite loss.

	Study reveals long-term health risks after chemotherapy for testicular cancer A large, multi-center study recently published online in the Journal of the National Comprehensive Cancer Network (JNCCN) provides new insight into the long-term health effects of contemporary chemotherapy regimens used to treat testicular cancer, highlighting differences in renal function, cardiovascular risk, and the overall burden of chronic health conditions among survivors.

	Changes in lymphatic vessels can help identify aggressive oral cancer at an early stage Oral cancers are the most common malignant tumors in the head and neck region, causing more than 188,000 deaths worldwide each year.

	Distinct gut toxicity patterns emerge with targeted cancer treatments A new paper was published in Volume 13 of Oncoscience on February 6, 2026, titled "Gastrointestinal toxicity of targeted cancer therapies in the United States: Clinicopathologic patterns, FDA safety frameworks, and implications for national patient protection."

	Study finds microplastics in most prostate tumors Small fragments of plastic were found in nine out of 10 patients with prostate cancer, and in higher levels inside tumors than in nearby noncancerous tissue, a new study finds.

	Detecting the "scent" of ovarian cancer with AI Using machine learning, an electronic nose can "smell" early signs of ovarian cancer in the blood. The method is precise and, according to the LiU researchers behind the study, it could eventually be used to find many different cancers. The study is published in the scientific journal Advanced intelligent systems.

	Blood test shows promise in forecasting outcomes for germ cell tumors Can fragments of tumor DNA in the blood predict whether chemotherapy will be effective? Researchers at the Princess Máxima Center investigated this question together with experts from Italy and Slovakia.

	Low-field MRI could offer an alternative to existing breast cancer screening methods Mass General Brigham's evaluation of low-field MRI performance lays potential groundwork for this technology to be a lower-cost, accessible option for breast imaging.

	Ochsner MD Anderson Cancer Center delivers Louisiana’s first TIL therapy for melanoma Ochsner MD Anderson Cancer Center at The Gayle and Tom Benson Cancer Center in New Orleans announces a milestone in advanced cancer treatment, as the first institution in Louisiana to provide an adult patient with tumor-infiltrating lymphocytes (TIL) therapy for advanced melanoma.

	New EANM award supports alpha radioligand therapy research Applications are now open for the 2026 EANM Young Scientist Network Award. This new research award, supported by Advanced Accelerator Applications (a Novartis company), aims to accelerate innovative research in alpha radioligand therapy (α-RLT) in prostate cancer.

Why did you receive this email?
You are receiving this email because you subscribed to updates from AZoNetwork UK Ltd. on one of our websites and requested to be notified of additional information.

Unsubscribe or Update Notification Preferences

Contact | About | Privacy Policy

- - - - - -

Registered Address:
AZoNetwork UK Ltd.,

Manchester | Sydney | Boston

Copyright © 2000-2026